President Donald Trump announced a plan to impose tariffs on generic drugs imported into the U.S., starting with a zero percent rate for two years beginning August 1, 2026, and escalating to 100% in August 2028 before doubling to 200% the following year. This phased tariff schedule aims to incentivize generic drug manufacturers to relocate production to the U.S., framing the tariffs as penalties for companies that do not establish domestic production facilities during the grace period. The proposal forms part of Trump's broader strategy to reshore pharmaceutical manufacturing in America, a move that brings significant challenges given the complexity and high cost of building drug production infrastructure onshore.

Almost all generic drugs prescribed in the U.S. are currently manufactured overseas, involving intricate global supply chains and ownership structures. While Trump’s earlier tariffs targeted patented and branded pharmaceuticals at a 100% rate from April 2026, generics and biosimilars were initially exempted. However, this new announcement signals a tougher stance aimed specifically at the generic drug market. Industry experts, such as Deborah Elms from the Hinrich Foundation, caution that even a 200% tariff may not sufficiently alter the cost dynamics given that most raw materials for pharmaceuticals still come from abroad, making true onshoring economically difficult.

India stands to face significant repercussions if these tariffs come into full effect, as it supplies nearly half of the generic medicines consumed in the U.S. and accounts for roughly one-third of India’s pharmaceutical exports. Indian drugmakers are concerned about the impact on their trade balance and export revenues, with fears that some manufacturers might withdraw from certain drug lines if added costs cannot be absorbed by wholesalers or consumers. Despite the looming threat, the two-year tariff delay offers a crucial window for New Delhi to negotiate with the U.S., potentially securing tariff exemptions in exchange for investment commitments on American soil.

In response to these trade pressures, Indian pharmaceutical companies are expected to intensify lobbying efforts in Washington, pursue additional approvals from the U.S. Food and Drug Administration, and seek contract manufacturing deals to maintain access to the U.S. market. Diversifying into other global markets is also anticipated as a strategic hedge against the risk of full tariff implementation. Furthermore, since the crucial 2028 tariff imposition would coincide with a U.S. election year, Indian officials hope political shifts could influence whether the policy is ultimately enforced.